Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study

References

• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65(3 Suppl):iii35-44
   PubMedGoogle Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
   PubMed Web of Science ®Google Scholar
• Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009;34(1 Suppl):S24-9
   Google Scholar
• Cainzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections–are they applicable today? Clin Microbiol Infect 2008;14(6 Suppl):9-18
   PubMedGoogle Scholar
• Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med 2007;74(4 Suppl):S21-8
   Google Scholar
• Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008;29:160-9
   PubMed Web of Science ®Google Scholar
• Marton JP, Jackel JL, Carson RT, et al. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin 2008;24:2821-8
   PubMed Web of Science ®Google Scholar
• Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008;14(3 Suppl):15-21
   PubMedGoogle Scholar
• Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis 2014;79:266-72
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012;50:238-45
   PubMed Web of Science ®Google Scholar
• Nathwani D, Eckmann C, Lawson W, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect 2014. doi: 10.1111/1469-0691.12632. [Epub ahead of print]
   Web of Science ®Google Scholar
• Menzin J, Marton JP, Meyers JL, et al. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control 2010;38:44-9
   PubMed Web of Science ®Google Scholar
• Itani KM, Merchant S, Lin SJ, et al. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control 2011;39:42-9
   PubMed Web of Science ®Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013;19:E377-85
   PubMed Web of Science ®Google Scholar
• Goetghebeur M, Landry PA, Han D, et al. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007;18:27-34
   PubMed Web of Science ®Google Scholar
• World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Country-specific unit costs. http://www.who.int/choice/country/country_specific/en/. Accessed April, 2013
   Google Scholar
• Tarricone R, Aguzzi G, Capone A, et al. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. J Med Econ 2008;11:265-79
   PubMedGoogle Scholar
• McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 2007;29:469-77
   PubMed Web of Science ®Google Scholar
• Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;165:1756-61
   PubMed Web of Science ®Google Scholar
• Sreeramoju P, Porbandarwalla NS, Arango J, et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg 2011;201:216-20
   PubMed Web of Science ®Google Scholar
• Souyri C, Olivier P, Grolleau S, et al. French Network of Pharmacovigilance Centres: severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol 2008;33:249-55
   PubMed Web of Science ®Google Scholar
• Schurmann D, Sorensen SV, De Cock E, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ 2009;10:65-79
   PubMed Web of Science ®Google Scholar
• De Cock E, Sorensen S, Levrat F, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med Mal Infect 2009;39:330-40
   PubMed Web of Science ®Google Scholar
• De Angelis G, Murthy A, Beyermann J, et al. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect 2010;16:1729-35
   PubMed Web of Science ®Google Scholar
• Shardell M, Harris AD, El-Kamary SS, et al. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007;45:901-7
   PubMed Web of Science ®Google Scholar